Session Title: Vasculitis
Session Type: Abstract Submissions (ACR)
Background/Purpose: It’s a known fact that serum levels of the tumor necrosis factor Alfa (TNF-α) interleucin-6 (IL-6) and other proinflammatory cytokines which are released from the adipose tissue are increased in Behcet’s disease (BD). In BD adipose tissue is nor a passive energy depot, it is an active endocrine organ and releases adipositokines. Visfatine is one of them. Visfatin is realted to TNF-α and IL-6, IL-1 beta, co-stimulators like CD40, CD54 and CD 80 and endothelial ICAM-1 and ICAM-2. We aimed to search the relation among levels’ of visfatin with activity of BD.
Methods: 60BD (30 patients were in active state and 30 were in remission) patients diagnosed according to The Criteria of Working Group on International BD and 20 health subjects as controls were involeved in to the study. The study of groups detected visfatin levels were compared among groups.
Results: Visfatin levels were significantly higer in both group of patients compared to the control group (both p<0,001) . Serum visfatin levels in patients with active than in inactive patients were found statistically significantly higher (p <0.001). The same way in all cases statistically significant correlation between visfatin and CRP (p <0.001) and visfatin and ESR (p<0.01). Only according to the symptoms of the patients in the active group compared to visfatin levels in patients with genital aphth visfatin levels, a statistically significantly higher than in patients without genital aphth were detected (p<0,001).
Conclusion: Serum visfatin levels in patients with active and inactive causes are higher than the control group; visfatin proinflammatory cytokines have a role in chronic inflammatory reaction, and to sustain the cellular expression of the inflammatory stokinlerin concluded that induce or be due to different reasons.
M. E. Enecik,
S. C. Sandikci,
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-importance-of-the-serum-visfatin-levels-in-behcets-disease-patients/